Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/33766

Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population

Título :
Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population
Autor :
Fernandez-Diaz, Eva  
Perez-Vicente, Jose A.
VILLAVERDE GONZALEZ, RAMON  
Berenguer Ruiz, Leticia  
Candeliere Merlicco, Antonio  
Martinez-Navarro, Maria Luisa
Gracia Gil, Julia  
Romero-Sanchez, Carlos M.
Alfaro Sáez, Arantxa  
Diaz, Inmaculada
Gimenez‑Martinez, Juana
Mendez-Miralles, Maria Angeles
Millan-Pascual, Jorge
Jimenez-Pancho, Javier
Mola, Santiago  
Sempere, Angel P.
Editor :
Wiley Periodicals LLC
Departamento:
Departamentos de la UMH::Medicina Clínica
Fecha de publicación:
2021
URI :
https://hdl.handle.net/11000/33766
Resumen :
Objective: Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited. The aim of this study was to evaluate the preliminary safety profile and effectiveness of ocrelizumab treatment for multiple sclerosis (MS) in a real-world clinical setting. Methods: We conducted a retrospective study including consecutive patients from nine public hospitals in south-eastern Spain who received ocrelizumab after it was approved. Results: A total of 228 MS patients were included (144 with relapsing–remitting MS [RRMS], 25 secondary progressive MS [SPMS], and 59 primary progressive MS [PPMS]). Median follow-up period was 12 months (range, 1-32). No evidence of disease activity (NEDA) status at year 1 was achieved in 91.2% of the relapsing MS (RMS) population, while disability progression was detected in 37.5% of the PPMS patients (median follow-up period, 19 months). The most common adverse events reported were infusion-related reactions and infections, with the most common infections being urinary tract infections followed by upper respiratory infections and COVID-19. Interpretation: The preliminary results in our real-world setting show that ocrelizumab presented excellent results in suppressing disease activity with a favorable and consistent safety profile.
Palabras clave/Materias:
Esclerosis múltiple
ocrelizumab
Área de conocimiento :
CDU: Ciencias aplicadas: Medicina
Tipo documento :
application/pdf
Derechos de acceso:
info:eu-repo/semantics/openAccess
DOI :
https://doi.org/10.1002/acn3.51282
Aparece en las colecciones:
Artículos Medicina Clínica



Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.